NCT04586673View on ClinicalTrials.gov

A Study to Assess Safety and Immunogenicity of Conserved Mosaic HIV-1 Vaccines

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 3, 2021

Primary Completion Date

August 3, 2022

Study Completion Date

August 3, 2022

Conditions
HIV
Interventions
BIOLOGICAL

ChAdOx1.tHIVconsv1 (C1)

ChAdOx1.tHIVconsv1 5 x 10\^9 vp

BIOLOGICAL

ChAdOx1.tHIVconsv1 (C1)

ChAdOx1.tHIVconsv1 5 x 10\^10 vp

BIOLOGICAL

MVA.tHIVconsv3 (M3)

MVA.tHIVconsv3 1 x 10\^8 pfu

BIOLOGICAL

MVA.tHIVconsv4 (M4)

MVA.tHIVconsv4 09. x 10\^8 pfu

Trial Locations (1)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER